Datalec Precision Installations (DPI) Announces Wholly Owned ACCS Manufacturing Plant
12.10.2021 13:02:00 EEST | Business Wire | Press release
Datalec Precision Installations (DPI), a provider of world-class data centre design, supply, build, and support services to deliver seamless, integrated and unified end-to-end solutions for data centre operators, announces its latest investment in a wholly owned subsidiary, managed by Yuriy Vasylkivskyy, that will deliver hot and cold aisle containment and caging solutions to the data centre industry. This solely owned and operated manufacturing facility is 35,000 square feet and is designed to operate 24/7 based on increasing demand for data centre components.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211012005077/en/
Datalec's Aerial Photo of the ACCS Manufacturing plant for aisle containment and cage solutions located in the UK (Photo: Business Wire)
Datalec’s ACCS manufacturing has been constructing metal cages and proprietary hot and cold aisle containment solutions and other specialist components. Originally performing an ‘assemble onsite’ facility, Datalec’s manufacturing plant has progressed into a fully-fledged offsite design, manufacturing and construction facility. The facility can efficiently produce prefabricated components and pre-terminated cables which can then be delivered to data centres throughout Europe for final on-site construction. Europe has seen a tremendous growth in data centre development causing the demand in data centre components to rise. The constraints in the supply chain significantly impact the building process and affect the European data centre market. Datalec’s investment directly addresses supply chain challenges, improving delivery timeframes and giving much needed momentum to the industry.
The ACCS manufacturing plant has profound benefits for Datalec’s business and supports the European data centre market well. As it relates to larger projects, it can lessen the overall impact of a supply chain known to be under pressure. By purchasing in advance raw materials required in data centre fit out projects, anticipating commodity price fluctuations and managing the product cost accordingly for end-users, ACCS can add significant value. Core to Datalec’s values is the constant pursuit of perfection and customer satisfaction is paramount. Responding to client demands, there are plans underway to construct a powder coating line further ensuring an output quality of the highest possible level.
For more information about DPI’s ACCS Manufacturing Plant, please visit https://datalecltd.co.uk/.
About Datalec
Datalec Precision Installations delivers excellence in international data centre installations, partnering with clients to make their businesses successful while providing seamless, integrated, unified end-to-end results with a ‘One Call, One Team’ service. DPI’s rigorous project management and supervision ensures projects are implemented to perfection the first time, every time, while mitigating risk and reducing cost for clients. DPI is focused on delivering a proactive and personal service that provides agility, flexibility and adaptability for substantial data suite construction and implementations. For more information visit: https://datalecltd.co.uk/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005077/en/
Contact information
Media Contact
Ilissa Miller
iMiller Public Relations
Email: datalec@imillerpr.com
Tel: 1.914.315.6424
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom